Vasca clears FDA warning letter issues:
This article was originally published in Clinica
Executive Summary
Vasca, which develops the LifeSite haemodialysis access system, says it has resolved issues relating to a November 2001 warning letter from the FDA. Earlier this month, the Tewksbury, Massachusetts-based company became the subject of a lawsuit relating to the warning letter as well as sales of the product (see Clinica No 1019, p 13). The FDA says the company has taken appropriate corrective action, including making a labelling change for the product.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.